<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[11, 15] postoperative rectal cancer patients<br>[52, 56] postoperative rectal cancer patients<br>[69, 88] Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without oxaliplatin<br>[106, 113] Two hundred and twenty-eight patients<br></td>
<td width=33%>
[11, 21] postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy]<br>[52, 67] postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT).<br>[69, 88] Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without oxaliplatin<br>[106, 113] Two hundred and twenty-eight patients<br></td>
<td width=33%>
[11, 21] postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy]<br>[52, 68] postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT).
<br>[69, 88] Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without oxaliplatin<br>[106, 113] Two hundred and twenty-eight patients<br>[231, 235] 136 patients presented severe<br>[368, 375] cases with GG or GA genotypes.<br>[388, 392] patients with AA genotype<br>[457, 465] postoperative stage II and III rectal cancer patients<br></td>
</tr>
